VKTX FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Viking Therapeutics in a research note issued to investors on Thursday, October 23rd. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biotechnology company will post earnings of ($2.87) per share for the year, down from their prior estimate of ($2.72). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Viking Therapeutics’ FY2026 earnings at ($4.83) EPS.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). Viking Therapeutics’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) EPS.

Several other equities analysts have also weighed in on the stock. Morgan Stanley boosted their target price on shares of Viking Therapeutics from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $125.00 target price on shares of Viking Therapeutics in a report on Monday, September 22nd. HC Wainwright reiterated a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Monday, September 29th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a report on Friday, October 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $85.62.

Viking Therapeutics Price Performance

NASDAQ:VKTX opened at $34.93 on Monday. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -16.48 and a beta of 0.64. The company’s 50-day moving average is $28.66 and its two-hundred day moving average is $29.02. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $79.10.

Institutional Investors Weigh In On Viking Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VKTX. Cambridge Investment Research Advisors Inc. increased its stake in Viking Therapeutics by 121.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock worth $718,000 after buying an additional 16,302 shares during the period. JNBA Financial Advisors purchased a new stake in Viking Therapeutics during the 1st quarter worth approximately $56,000. Bank of New York Mellon Corp increased its stake in Viking Therapeutics by 12.0% during the 1st quarter. Bank of New York Mellon Corp now owns 518,298 shares of the biotechnology company’s stock worth $12,517,000 after buying an additional 55,334 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in Viking Therapeutics during the 1st quarter worth approximately $220,000. Finally, Envestnet Asset Management Inc. increased its stake in Viking Therapeutics by 15.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 48,139 shares of the biotechnology company’s stock worth $1,163,000 after buying an additional 6,294 shares during the period. 76.03% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Viking Therapeutics

In other news, COO Marianna Mancini sold 6,185 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $35.00, for a total value of $216,475.00. Following the sale, the chief operating officer directly owned 382,467 shares of the company’s stock, valued at approximately $13,386,345. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Lian sold 38,989 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $35.01, for a total transaction of $1,365,004.89. Following the completion of the sale, the chief executive officer directly owned 2,419,109 shares in the company, valued at $84,693,006.09. This trade represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 111,359 shares of company stock valued at $3,932,155 over the last 90 days. Insiders own 4.10% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.